Paradigm Biopharmaceuticals (DB:P86) - Stock Price, News & Analysis

P86 Stock Overview

Engages in the research and development of therapeutic products for human use in Australia. More details

P86 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months compared to the German market

Makes less than USD$1m in revenue (A$0)

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 2 more risks

Paradigm Biopharmaceuticals Limited Competitors

Medigene

XTRA:MDG1

€23.2m

4SC

DB:VSC

€58.0m

Heidelberg Pharma

XTRA:HPHA

€104.4m

2invest

XTRA:2INV

€63.8m

Price History & Performance

Summary of all time highs, changes and price drops for Paradigm Biopharmaceuticals
Historical stock prices
Current Share Price	AU$0.17
52 Week High	AU$0.19
52 Week Low	AU$0.10
Beta	0.87
11 Month Change	24.81%
3 Month Change	24.81%
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	15.68%

Recent updates

Shareholder Returns

	P86	DE Biotechs	DE Market
7D	17.7%	0.8%	-0.4%
1Y	n/a	-16.7%	7.1%

Return vs Industry: Insufficient data to determine how P86 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how P86 performed against the German Market.

Price Volatility

Is P86's price volatile compared to industry and market?
P86 volatility
P86 Average Weekly Movement	14.1%
Biotechs Industry Average Movement	6.3%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: P86's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine P86's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2014	n/a	Paul Rennie	www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.

Paradigm Biopharmaceuticals Limited Fundamentals Summary

How do Paradigm Biopharmaceuticals's earnings and revenue compare to its market cap?
P86 fundamental statistics
Market cap	€60.52m
Earnings (TTM)	-€36.18m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.7x

P/E Ratio

Is P86 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
P86 income statement (TTM)
Revenue	AU$0
Cost of Revenue	AU$8.99k
Gross Profit	-AU$8.99k
Other Expenses	AU$58.64m
Earnings	-AU$58.65m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.17
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did P86 perform over the long term?

See historical performance and comparison

Paradigm Biopharmaceuticals DB:P86 Stock Report